tetano
Editor, Senior Moderator
Int J Rheum Dis
. 2024 May;27(5):e15166.
doi: 10.1111/1756-185X.15166. Efficacy and safety of inactivated SARS-CoV-2 vaccination in COVID-19-associated pneumonia among patients with rheumatic and musculoskeletal diseases: A real-world retrospective observational study
Shuman Liu[SUP] 1 [/SUP], Ziyi Jin[SUP] 2 [/SUP], Xuebing Feng[SUP] 2 [/SUP], Zhanyun Da[SUP] 3 [/SUP], Yu Tang[SUP] 4 [/SUP], Huaixia Hu[SUP] 5 [/SUP], Dandan Wang[SUP] 2 [/SUP], Lingyun Sun[SUP] 1 [/SUP]
Affiliations
Objectives: To identify the effectiveness and safety of inactivated SARS-CoV-2 vaccines in rheumatic and musculoskeletal diseases (RMDs) patients.
Methods: RMD patients with COVID-19 in Jiangsu Province were polled between December 8, 2022, and February 1, 2023. Information on demographics, disease characteristics, antirheumatic drug use, vaccination status and survival state were collected. COVID-19-associated pneumonia was the primary outcome. The effect of COVID-19 immunization on RMD patients was assessed using multivariate logistic regression, and the adverse events (AEs) following vaccination were evaluated.
Results: Among 592 RMD patients with COVID-19, 276 (46.6%) individuals experienced COVID-19-associated pneumonia, and 290 (49.0%) patients were injected with inactivated vaccines. In multivariate logistic regression analysis, vaccines reduced the incidence of COVID-19-associated pneumonia, and receiving booster vaccine was an independent protective factor for COVID-19-associated pneumonia in RMD patients (OR 0.64, 95% CI 0.41-0.98, p = .034). In particular, inactivated vaccines have a protective impact on RMD patients with a high risk of developing pneumonia, including those aged 45 years and older (OR 0.53, 95% CI 0.34-0.83), and who have lung involvement (OR 0.43, 95% CI 0.23-0.82). The total AEs rate of vaccines was 13.9% (40/290), only 11 (3.8%) experienced the recurrence or deterioration of RMDs, and no serious AEs occurred.
Conclusion: Inactivated COVID-19 vaccines were safe and effective in reducing the risk of COVID-19-associated pneumonia of RMD patients in China.
Keywords: COVID‐19; effectiveness; rheumatic and musculoskeletal diseases; safety; vaccination.
. 2024 May;27(5):e15166.
doi: 10.1111/1756-185X.15166. Efficacy and safety of inactivated SARS-CoV-2 vaccination in COVID-19-associated pneumonia among patients with rheumatic and musculoskeletal diseases: A real-world retrospective observational study
Shuman Liu[SUP] 1 [/SUP], Ziyi Jin[SUP] 2 [/SUP], Xuebing Feng[SUP] 2 [/SUP], Zhanyun Da[SUP] 3 [/SUP], Yu Tang[SUP] 4 [/SUP], Huaixia Hu[SUP] 5 [/SUP], Dandan Wang[SUP] 2 [/SUP], Lingyun Sun[SUP] 1 [/SUP]
Affiliations
- PMID: 38720417
- DOI: 10.1111/1756-185X.15166
Objectives: To identify the effectiveness and safety of inactivated SARS-CoV-2 vaccines in rheumatic and musculoskeletal diseases (RMDs) patients.
Methods: RMD patients with COVID-19 in Jiangsu Province were polled between December 8, 2022, and February 1, 2023. Information on demographics, disease characteristics, antirheumatic drug use, vaccination status and survival state were collected. COVID-19-associated pneumonia was the primary outcome. The effect of COVID-19 immunization on RMD patients was assessed using multivariate logistic regression, and the adverse events (AEs) following vaccination were evaluated.
Results: Among 592 RMD patients with COVID-19, 276 (46.6%) individuals experienced COVID-19-associated pneumonia, and 290 (49.0%) patients were injected with inactivated vaccines. In multivariate logistic regression analysis, vaccines reduced the incidence of COVID-19-associated pneumonia, and receiving booster vaccine was an independent protective factor for COVID-19-associated pneumonia in RMD patients (OR 0.64, 95% CI 0.41-0.98, p = .034). In particular, inactivated vaccines have a protective impact on RMD patients with a high risk of developing pneumonia, including those aged 45 years and older (OR 0.53, 95% CI 0.34-0.83), and who have lung involvement (OR 0.43, 95% CI 0.23-0.82). The total AEs rate of vaccines was 13.9% (40/290), only 11 (3.8%) experienced the recurrence or deterioration of RMDs, and no serious AEs occurred.
Conclusion: Inactivated COVID-19 vaccines were safe and effective in reducing the risk of COVID-19-associated pneumonia of RMD patients in China.
Keywords: COVID‐19; effectiveness; rheumatic and musculoskeletal diseases; safety; vaccination.